NASDAQ · Biotechnology · USD
SL Science Holding Limited (SLBT) Stock Analysis
SL Science Holding Limited (SLBT) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 22, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
SLBT Key Statistics
As of Oct 22, 2026Trading
- Open
- $1.41
- Previous Close
- $1.45
- Day's Range
- 1.31–1.41
- 52-Week Range
- 1.31–14.50
- Volume
- 32.00K
Valuation
- Market Cap
- $734.60M
- P/E Ratio
- unprofitable
- P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
- 224.64
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −0.01
Financials (FY)
- Revenue (FY)
- $2.20M−34.68%
- Net Income (FY)
- −$3.82M
- Profit marginThe share of revenue left as profit after all costs and taxes.
- −72.46%
- Shares Outstanding
- 560.76M
- 1-Year Return
- −87.37%
Dividend and dates
- Avg Volume
- 77.34K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 22, 2026, SLBT closed at $1.31, −87.37% over 1 year.
SL Science Holding Limited (SLBT) has a market capitalization of $734.60M.
In fiscal 2025, SLBT reported revenue of $2.20M.
SLBT Stock Return by Calendar Year
SL Science Holding Limited (SLBT) return since Feb 2025: what $10,000 became
- 1 year
- $10,000 $1,263
- −87.37%
- Since Feb 2025
- $10,000 $1,307
- −86.93%
If you had invested $10,000 in SL Science Holding Limited (SLBT) at the close on February 5, 2025, the earliest close on record here, it would have been worth $1,307 at the close on October 22, 2026: −86.93% in total, −69.61% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −87.58% |
| 2025 (partial year) | +5.24% |
As of October 22, 2026.
SLBT Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $2.20M | −$3.82M | −173.8% |
| 2024 | $3.36M | −$1.19M | −35.4% |
| 2023 | $878.97K | $399.04K | 45.4% |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $2.20M | $775.06K | −$3.84M | −$3.82M | −173.8% |
| 2024 | $3.36M | $1.93M | −$1.20M | −$1.19M | −35.4% |
| 2023 | $878.97K | $738.01K | $96.83K | $399.04K | 45.4% |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
SLBT Valuation vs Biotechnology Median
Median of 607 stocks| Metric | SLBT | Biotechnology median | vs median |
|---|---|---|---|
| P/S ratio | 224.64 | 13.26 | 16.9x the median |
| Profit margin | −72.46% | −38.31% | 34.1 pts below |
Medians across 607 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 22, 2026.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 22, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$135.64B
REGNRegeneron Pharmaceuticals, Inc.
$84.33B
MRNAModerna, Inc.
$80.90B
ARGXargenx SE
$55.07B
ONCBeOne Medicines AG
$43.49B
RVMDRevolution Medicines, Inc.
$40.23B
Popular Healthcare Stocks
Eli Lilly and Company
$1.17T
JNJJohnson & Johnson
$644.91B
ABBVAbbVie Inc.
$503.96B
UNHUnitedHealth Group Incorporated
$381.46B
MRKMerck & Co., Inc.
$363.27B